Complications of the Surgical Management of Children with Neuroblastoma

MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma

“…It is the third most common pediatric cancer, after leukemia and brain cancers [4]. Furthermore, neuroblastoma tumors are able to mature spontaneously, and there are certain phenotypes, dubbed "ultra high risk" that tend to have increased resistance to therapy [5][6][7]. The International Neuroblastoma Risk Group classification system [8] was developed to aid in the clinical management of pediatric neuroblastoma.…”

“…Based on molecular and clinical features, patients are grouped into either low, intermediate, or high risk groups, with high risk groups having poor survival outcomes. Thus, there is a need to identify biological characteristics that may help better inform clinicians regarding the risk-status of the neuroblastoma patients [5]. In this report, we examined the connection between Tau expression in neuroblastoma and survival rates.…”

miR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNF4α

“…It occurs mainly in the abdomen, mediastinum and neck of children and is the most common extracranial solid tumour in children [1]. The incidence of neuroblastoma in children under 15 years old was 10.54/100,000, ranking the first in peripheral nervous system malignancies in children [2]. Neuroblastoma is characterized by high degree of malignancy, rapid development, strong invasion and great differences in clinical manifestations.…”

HOTAIR gene polymorphisms contribute to increased neuroblastoma susceptibility in Chinese children

“…Neuroblastoma, an embryonic cancer of the sympathetic nervous system, is the most common malignancy diagnosed during the first year after birth and the most frequent extracranial solid tumor in children. 1,2 Neuroblastoma accounts for approximately 8% of all malignancies in children aged <15 years, with an incidence of 10 cases per 1 million children in the United States. 2 In China, neuroblastoma represents approximately 10% of childhood tumors, with an incidence of approximately 7.7 cases per 1 million children.…”

“…1,2 Neuroblastoma accounts for approximately 8% of all malignancies in children aged <15 years, with an incidence of 10 cases per 1 million children in the United States. 2 In China, neuroblastoma represents approximately 10% of childhood tumors, with an incidence of approximately 7.7 cases per 1 million children. 3 Despite marked improvements in multimodality treatment for neuroblastoma, the 5-year survival rate remains at 70% and, especially for patients with high-risk neuroblastoma, the cure rate remains at <40%.…”